UBS Group
AEON icon

UBS Group’s AEON Biopharma AEON Stock Holding History

UBS Group’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64K Buy
5,062
+880
+21% +$736 ﹤0.01% 9163
2026
Q1 		$4.12K Buy
4,182
+130
+3% +$145 ﹤0.01% 8985
2025
Q4 		$4.46K Buy
4,052
+2,860
+240% +$2.67K ﹤0.01% 8834
2025
Q3 		$964 Sell
1,192
-30,408
-96% -$23.4K ﹤0.01% 9480
2025
Q2 		$24K Buy
31,600
+28,643
+969% +$16.4K ﹤0.01% 8319
2025
Q1 		$1.72K Buy
2,957
+2,279
+336% +$16.2K ﹤0.01% 9460
2024
Q4 		$26.4K Sell
678
-122
-15% -$7.11K ﹤0.01% 7704
2024
Q3 		$60.5K Buy
+800
New +$70.4K ﹤0.01% 6690
2024
Q1 		– Sell
-9
Closed -$4.67K – 9237
2023
Q4 		$4.67K Buy
+9
New +$3.61K ﹤0.01% 7837
2023
Q1 		– Sell
-11
Closed -$8.06K – 9538
2022
Q4 		$8.06K Sell
11
-33
-75% -$23.6K ﹤0.01% 8822
2022
Q3 		$32K Buy
44
+29
+193% +$20.5K ﹤0.01% 6785
2022
Q2 		$11K Hold
15
– – ﹤0.01% 7777
2022
Q1 		$11K Buy
+15
New +$10.5K ﹤0.01% 8280

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's AEON Position: Q2 2026 in Review

UBS Group increased its AEON Biopharma (AEON) stake by 21% in Q2 2026, buying an estimated $736 and bringing the position to 5,062 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #9163.

UBS Group first reported a position in AEON in Q1 2022 and has held it in 13 quarters since. The position peaked at $60.5K in Q3 2024. 22 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

  • UBS Group held 5,062 shares of AEON Biopharma worth $3.64K as of Q2 2026.
  • UBS Group bought 880 AEON Biopharma shares in Q2 2026, an estimated $736.
  • AEON Biopharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9163 holding.
  • UBS Group first reported a position in AEON Biopharma in Q1 2022 and has held it in 13 quarters since.
  • UBS Group's AEON Biopharma position peaked at $60.5K in Q3 2024.
  • 22 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.